At its Annual General Meeting (AGM) held on April 15, 2026, shareholders of Molecular Partners AG approved all proposals put forward by the Board of Directors. The Swiss biotech company, listed on the SIX Swiss Exchange, announced the results following the meeting.
A key outcome was the election of Clare Fisher as a new independent member of the Board of Directors. Fisher brings extensive experience in the life sciences and financial sectors. The remaining members of the Board of Directors were also re-elected for a further one-year term.
In addition to the board elections, shareholders approved the company's annual report, financial statements, and discharge of the Board and Executive Committee for the 2025 financial year. The AGM also approved the proposed maximum aggregate compensation for the Board and Executive Committee for the upcoming term.
The meeting followed the company's recent business updates, which have focused on the clinical development of its DARPin therapeutic candidates. Molecular Partners is advancing treatments in oncology and other disease areas.
